OptiNose, Inc. (OPTN) Hits All-Time High at $28.26

June 29, 2018 - By Norman Soto

OptiNose, Inc. (NASDAQ:OPTN) touched $28.26 price per share on Jun, 29, also an all time high. This chart pattern was announced by Barchart.com. OptiNose, Inc. (NASDAQ:OPTN) has $1.15 billion MC. The valuation of NASDAQ:OPTN can change by $57.65M if our $29.67 price target is touched.

Ticker’s shares touched $28.26 during the last trading session after 0.70% change.OptiNose, Inc. has volume of 46,133 shares. Since June 29, 2017 OPTN has 0.00% and is . The stock underperformed the S&P500 by 12.57%.

OptiNose, Inc. (NASDAQ:OPTN) is anticipated to reveal earnings on August, 13., according to RTT. Analysts at Wall Street see OptiNose, Inc.’s -2.47 % EPS growth compared to $-0.81 earnings per share for previous quarter.

For more OptiNose, Inc. (NASDAQ:OPTN) news brought out briefly go to: Benzinga.com, Nasdaq.com, Globenewswire.com, Streetinsider.com or Globenewswire.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” brought out on June 29, 2018, “Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals” on June 21, 2018, “Optinose Announces Pricing of Public Offering of Common Stock” with a publish date: June 07, 2018, “OptiNose (OPTN) Commences 4.5M Share Offering of Common Stock” and the last “Optinose Announces Launch of Public Offering of Common Stock” with publication date: June 04, 2018.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The company has $1.15 billion market cap. The firm offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.Currently it has negative earnings. It also markets Onzetra Xsail for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.